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part in the wtiology of pregnancy toxwmia. It is impossible to say, however, whether this rise is the primary factor in toxemia or whether it is secondary to placental damage produced by some other mechanism. Whichever of these possibilities is true, treatment with a 5-HT antagonist might be beneficial in this condition, and we are considering such an investigation.
It is of interest that Klinge et al. (1964) found no difference between the 5-HT content of the placentae of normal and toxaemic women. The values they obtained were, however, much lower than ours, so that it is not really possible to compare the two series of results. There is also evidence that pregnant women who suffer from habitual abortion excrete larger quantities of 5-hydroxyindole acetic acid (5-HIAA) a metabolite of 5-HT, than do normal pregnant women. Moreover heat stress sometimes markedly increases the excretion of 5-HIAA in the women with habitual abortion while such stress does not increase the excretion of the metabolite in normal women (Sadowsky et al. 1963 ). The authors suggest that 5-HT may be involved in inducing habitual abortion.
Conclusion 5-Hydroxytryptamine (5-HT) produces a number of toxic effects on the foetus when injected into pregnant mice, rats or rabbits. The main effect seems to be a reduction of placental blood flow and transfer function, and this may result either in fcetal death or in the production of congenital malformations. Which of these effects predominates depends on the time of administration and the dose of 5-HT used. Both effects can be prevented by the prior administration of 5-HT antagonists, e.g. methysergide, cyproheptadine or SQ 10643. Some of these effects are compared with those following the administration of adrenaline.
It has been shown that the 5-HT content of the human placenta is raised in cases of toxaemia and it is suggested that it would be worth while to investigate the use of 5-HT antagonists in this condition. The most obvious effects of adrenaline are exerted on the cardiovascular system. However, in many organs the amine also induces a profound change in tissue metabolism and, indeed, the prime function of adrenaline in homeostasis may be exerted through metabolic rather than vascular effects. This paper discusses the results of some in vitro studies of the effect of adrenaline on placental metabolism in man and rat. Slices of placental tissue received at vaginal delivery, CQsarean section or hysterotomy were incubated as described by Ginsburg & Jeacock (1964) . In view of the well-known glycogenolytic effects of adrenaline and its ability to release lactic acid from tissues such as skeletal muscle and adipose tissue, the initial studies were concerned with some aspects of carbohydrate metabolism, namely lactate production, glycogen breakdown and glucose uptake. Placental lactic acid output, glycogen content and glucose uptake were determined by the methods described by Ginsburg & Jeacock (1966a) . itself. However, the fact that mean glucose uptake PLAETAER was not decreased in the presence of adrenaline, PLACENTAE even in early placenta, and that no glucose was detected in the media when placental tissue was incubated with adrenaline in the absence of 4p glucose (Ginsburg & Jeacock 1964) , does not support the concept of the placenta as the biochemical counterpart of the liver. Indeed, consideration of some of the metabolic responses to adrenaline in the human placenta suggests a closer affinity with skeletal muscle than with liver. Adrenaline causes a considerable increase in placental lactate production, as indicated by the liberation of lactic acid into the medium, approximately the same amount being liberated from early as from term placentae (Fig 1) . The effect of adrenaline on placental lactate production was dependent on the dose used, very much more lactate being evolved with the extremely high concentration of 40 pg/ml adrenaline than with 10 ,ug/ml, though a significant increase in lactate output was still observed with only 0-625 ,ug/ml (Ginsburg & Jeacock 1964) . Placental lactate output under the influence of adrenaline alone was not maximal, for when placental tissue was incubated in anaerobic conditions, lactate output increased further (Fig 2) . An increase in lactate production was not the only change in placental metabolism induced by adrenaline. Glucose uptake was also increased when placental tissue was incubated with adrenaline, the effect being most marked with the higher doses of the amine.
Since Claude Bernard's demonstration of the presence of glycogen in early placenta: (Bernard 1859), the placenta has been considered, at least in the early stages of gestation, as an auxiliary
The glycogen content of the placenta decreased on incubation of the tissue, but there was a further decrease in placental glycogen content when adrenaline was added to the incubation medium, the decrease in glycogen content being dependent on the dose of adrenaline used. It is reasonable to assume that at least some of the extra lactate released by adrenaline is derived from the breakdown of tissue glycogen. A further proportion must also be derived from the glucose in the incubation medium, for very much less lactate was evolved in the absence of glucose than in its presence. However, the precise contribution of added glucose substrate to the excess placental lactate liberated under the influence of adrenaline can only be determined from studies with labelled substrate, together with measurement of the intermediary products of metabolism.
From the clinical point of view, increased liberation of lactate by the placenta may be of some consequence. Maternal systemic levels of lactate are increased in both pregnancy and labour (Hendricks 1957) but hitherto it has been believed that the rise in maternal venous lactate is due mainly to anoxic metabolism in the smooth muscle ofthe uterus. The present studies, however, suggest that a contributory factor could be the release of lactate from the placenta itself. The possibility should also be considered that altered placental lactate may contribute to acidosis in the new-born, especially after long labour. In this connexion, it is relevant that, in diabetes mellitus, where the infant is particularly vulnerable to neonatal acidosis, placental lactate production was significantly greater than in normal placente and increased further in the presence of adrenaline (Ginsburg & Jeacock 1965 , 1966a . Inherent in any discussion of the clinical consequences of altered placental lactate production is the direction of transfer of excess lactate produced by the placenta, but on this score there is unfortunately no quantitative information. In order, therefore, to evaluate the effects of altered placental lactate production on maternal or foetal lactate levels, the relative transfer of the metabolite across the placental barrier, in either direction, will have to be determined. The possibility that at least some lactate may move in the direction of the feetus, is suggested by the very high concentration of lactic acid in the amniotic fluid (Hendricks 1957) . The alteration in placental metabolism induced by adrenaline must also affect the energy potential of the placenta and hence influence placental transfer mechanisms, though whether this will enhance or depress foetal activity is not known.
In an attempt to elucidate some of these problems, studies were also undertaken of the effect of adrenaline on metabolic processes in the rat placenta (Ginsburg & Jeacock 1966b) . Lactate production in rat placente was very much higher than in human placente and was not increased further with adrenaline, or after incubation in anaerobic conditions. Glucose uptake was also much higher in rat placents than in human and was not increased by the addition of adrenaline. These findings emphasize Sir Joseph Barcroft's (1946) warning of 'the danger of arguing from a single species' and underline the importance of using human tissue for the evaluation of human placental function.
